Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (231-240 of 346) with videos related to

Pageof 35
Sort By:
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
British Journal of Haematology|February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemiaSanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
Cancer|August 2, 2016
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Blood Cancer Journal|May 28, 2020
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALLNicholas J Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Pageof 35

Showing results (231-240 of 346) with videos related to

Sort By:
Pageof 35
Blood Cancer Journal|September 30, 2021
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangementsGhayas C Issa, Jabra Zarka, Koji Sasaki, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatmentHussein A Abbas, Edward Ayoub, Hanxiao Sun, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
British Journal of Haematology|February 22, 2021
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemiaSanam Loghavi, Courtney D DiNardo, Ken Furudate, et al.
Cancer|August 2, 2016
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Elias J Jabbour, Farhad Ravandi, et al.
Blood Cancer Journal|May 28, 2020
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALLNicholas J Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, et al.
The Lancet. Haematology|May 15, 2023
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trialElias Jabbour, Nicholas J Short, Jayastu Senapati, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
American Journal of Hematology|September 10, 2022
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaSangeetha Venugopal, Courtney D DiNardo, Sanam Loghavi, et al.
Pageof 35